Genetics Unit, Shriners Hospital for Children, Montreal, Quebec, Canada.
J Bone Miner Res. 2010 Jun;25(6):1367-74. doi: 10.1359/jbmr.091109.
Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that in the majority of cases is caused by mutations in COL1A1 or COL1A2, the genes that encode the two collagen type I alpha chains, alpha1(I) and alpha2(I). In this study, we examined the relationship between collagen type I mutations and bone densitometric and histomorphometric findings in pediatric OI patients who had not received bisphosphonate treatment. Lumbar spine areal bone mineral density (LS aBMD) was measured in 192 patients (99 girls, 93 boys; age range 3 weeks to 16.9 years) who had either COL1A1 mutations leading to haploinsufficiency (n = 52) or mutations that lead to the substitution of glycine by another amino acid in the triple-helical domain of either the alpha1(I) (n = 58) or the alpha2(I) chain (n = 82). Compared with patients with helical mutations, patients with COL1A1 haploinsufficiency on average were taller and heavier and had higher LS aBMD. After adjustment for age, sex, and height Z-scores, the mean LS aBMD Z-scores were -4.0 for the haploinsufficiency group and -4.7 for both helical mutation groups. In the whole patient population, the average LS aBMD Z-score was higher by 0.6 (95% confidence interval 0.2-1.0) in girls than in boys. Iliac bone histomorphometry (in a subgroup of 96 patients) showed that outer bone size (core width) and trabecular bone volume were similar between genotypic groups, but cortical width was 49% higher in the haploinsufficiency group compared with patients with helical mutations in alpha2(I). Bone turnover parameters were lower in the haploinsufficiency group than in patients with helical mutations. In the group of patients with helical mutations, neither the type of alpha chain affected, nor the type of amino acid substituting for glycine, nor the position of the mutation in the alpha chain had a detectable relationship with LS aBMD or histomorphometric results. Thus patients with haploinsufficiency mutations had a milder skeletal phenotype than patients with mutations affecting glycine residues, but there was no clear genotype-phenotype correlation among patients with helical glycine mutations.
成骨不全症(OI)是一种遗传性骨骼脆弱疾病,大多数情况下是由 COL1A1 或 COL1A2 基因突变引起的,这两个基因编码两种Ⅰ型胶原α链,即α1(I)和α2(I)。在这项研究中,我们研究了未接受双膦酸盐治疗的儿科 OI 患者的Ⅰ型胶原基因突变与骨密度计量学和组织形态计量学结果之间的关系。对 192 名患者(99 名女孩,93 名男孩;年龄范围 3 周至 16.9 岁)的腰椎骨面积骨密度(LS aBMD)进行了测量,这些患者要么携带导致单倍体不足的 COL1A1 突变(n=52),要么携带导致α1(I)(n=58)或α2(I)链(n=82)三螺旋结构域中甘氨酸被另一种氨基酸取代的突变。与螺旋突变患者相比,COL1A1 单倍体不足患者的身高和体重平均更高,LS aBMD 也更高。在调整年龄、性别和身高 Z 评分后,单倍体不足组的平均 LS aBMD Z 评分为-4.0,两个螺旋突变组的平均 LS aBMD Z 评分均为-4.7。在整个患者人群中,女孩的平均 LS aBMD Z 评分比男孩高 0.6(95%置信区间 0.2-1.0)。髂骨组织形态计量学(在 96 名患者的亚组中)显示,基因型组之间的外骨大小(核心宽度)和小梁骨体积相似,但与α2(I)中螺旋突变患者相比,单倍体不足组的皮质宽度高 49%。与螺旋突变患者相比,单倍体不足组的骨转换参数较低。在螺旋突变患者组中,α 链的突变类型、取代甘氨酸的氨基酸类型或突变在α链中的位置均与 LS aBMD 或组织形态计量学结果无明显关系。因此,与影响甘氨酸残基的突变患者相比,单倍体不足突变患者的骨骼表型较轻,但在螺旋甘氨酸突变患者中,没有明确的基因型-表型相关性。